Masters in Business

Targeting IgA Nephropathy (Sponsored Content)

November 9, 2025

Key Takeaways Copied to clipboard!

  • IgA nephropathy (IgAN) is a progressive, chronic kidney disease often discovered incidentally through routine urine tests, as was the case for Rachel Benton, the patient featured in this episode of "Targeting IgA Nephropathy (Sponsored Content)" from the "Masters in Business" podcast. 
  • The disease mechanism involves the misdirection of IgA antibodies, which form immune complexes that clog and damage the kidney filters, leading to progressive function decline, with the majority of adult patients progressing to end-stage kidney disease within 20 years. 
  • Vertex Pharmaceuticals is actively researching IgAN by focusing on the role of B cell control, specifically targeting the proteins BAF and April, with the goal of developing transformative medicines to restore immune balance and halt disease progression. 

Segments

Introduction to Sponsored Content
Copied to clipboard!
(00:00:00)
  • Key Takeaway: The episode is part of a six-episode sponsored podcast series called “Targeting the Toughest Diseases” by Vertex Pharmaceuticals and Bloomberg Media Studios.
  • Summary: The episode is presented as part of a larger series exploring Vertex Pharmaceuticals’ philosophy and innovative tools used to find treatments for challenging diseases. This specific segment introduces the context of the sponsored content to the existing Bloomberg podcast subscribers. The series aims to highlight Vertex’s approach to tackling difficult medical conditions.
Rachel Benton’s Diagnosis Story
Copied to clipboard!
(00:00:30)
  • Key Takeaway: Rachel Benton’s IgA nephropathy was discovered via a routine urine test during pregnancy, which revealed protein in her urine, leading to a biopsy and diagnosis.
  • Summary: Rachel Benton, Stetson’s mother, recounts how a routine 24-hour urine test during pregnancy detected protein, prompting further investigation. The subsequent biopsy confirmed the diagnosis of IgA nephropathy (IgAN), a rare kidney disease with no known cure at the time of her diagnosis. The uncertainty following the diagnosis caused significant emotional distress regarding her future health and ability to parent.
Defining IgA Nephropathy
Copied to clipboard!
(00:02:26)
  • Key Takeaway: IgA nephropathy is a progressive chronic kidney disease characterized by IgA protein sludging up kidney filters, causing leakage of blood and protein into the urine.
  • Summary: IgAN is defined as a progressive chronic kidney disease that was historically underreported and under-researched. The disease involves the deposition of IgA protein aggregates in the kidney filters, leading to inflammation, scarring, and eventual decline in kidney function. A majority of adult patients are expected to progress to end-stage kidney disease requiring dialysis or transplant within 20 years of diagnosis.
Expert Insight on Disease Progression
Copied to clipboard!
(00:07:35)
  • Key Takeaway: Diagnosis currently requires a kidney biopsy, and the disease progression rate is highly variable, though a genetic component is suspected.
  • Summary: Dr. Jonathan Barrett notes that interest in IgAN research has significantly increased recently, as early stages are often asymptomatic. The disease pathology involves abnormal IgA from the gut/respiratory tract entering the bloodstream, forming immune complexes that clog the filters. While a genetic component exists, current diagnosis relies solely on biopsy, and predicting individual patient outcomes remains difficult.
Vertex’s Scientific Approach
Copied to clipboard!
(00:11:30)
  • Key Takeaway: Vertex targets IgAN by focusing on causal human biology, specifically investigating the role of BAF and April proteins in uncontrolled B cell activity.
  • Summary: Vertex Pharmaceuticals aims to develop transformative medicines by focusing on human-validated targets and utilizing any necessary scientific approach. Dr. Manish Maskey explains that B cells losing control is the mechanism leading to kidney injury, driven by elevated levels of the proteins BAF and April. Targeting these proteins offers the potential to restore immune balance and stabilize kidney function by reducing proteinuria and hematuria.
Patient Advocacy and Mental Health
Copied to clipboard!
(00:16:16)
  • Key Takeaway: The uncertainty of an incurable, progressive disease like IgAN places a significant burden on patients’ mental health, leading to feelings of guilt and fear for the future.
  • Summary: Rachel Benton expresses guilt over potentially not being a healthy mother or wife due to her unpredictable condition, highlighting the severe impact on mental wellness. She advocates for others to seek annual checkups and specifically request urine tests to catch early signs of the disease. Despite the challenges, she strives to remain positive and make the best of each day.